MedTrace Logo

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

NCT05171257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2026-03-27

No results posted yet for this study

Summary

Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeruginosa strain; however, the use of an agent with antipseudomonal activity would select for resistance to that particular antimicrobial agent or class. Demonstrated that each additional day of exposure to any antipseudomonal beta-lactam is associated with an increased risk of new resistance development.

The study seeks to determine whether the choice of empiric therapy (i.e., the same agent versus a different agent from prior antibiotic exposure) has any effect on the likelihood of in vitro activity against GN pathogens (GNPs) in a subsequent infection.

Conditions

  • Gram-Negative Bacterial Infections

Interventions

DRUG

IV antibiotic treatment from prior

patients receiving same IV antibiotic treatment from prior

DRUG

differing IV antibiotic treatment

patients receiving differing IV antibiotics from prior

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Mathew Crotty, MD · Methodist

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2025-07-14
Completion
2025-07-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171257 on ClinicalTrials.gov